STOCKHOLM3
LIVE

Serial Number

79317755

Owner

A3P Biomedical AB

Attorney

Sarah J. Schneider

Filing Date

Feb 9, 2021

Add to watchlist:

No watchlists yet
View on USPTO

STOCKHOLM3 Trademark

Serial Number: 79317755 • Registration: 6854609

STOCKHOLM3 is a trademark filed by A3P Biomedical AB on February 9, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

A3P Biomedical AB (4 trademarks)

Kungsgatan 24

Entity Type: 98

Trademark Details

Filing Date

February 9, 2021

Registration Date

September 27, 2022

Published for Opposition

July 12, 2022

Goods & Services

Recorded computer software for supporting diagnostic testing for and determination of risk stratification of prostate cancer; recorded computer program for analysing, displaying, modeling, and stratifying data from diagnostic blood tests and clinical data; instruments for diagnosis for scientific use, namely, diagnostic apparatus for testing biological specimens; parts and fittings for all the aforesaid goods included in this class

Medical and veterinary preparations and articles, namely, diagnostic blood test for risk stratification of prostate cancer; diagnostic preparations and materials for medical use; reagents for use in diagnostic tests for medical purposes; diagnostic testing materials for medical use, namely, medical diagnostic reagents and medical diagnostic assays for testing body fluids for determining the presence of certain protein and genetic markers; diagnostic test materials for prostate cancer, namely, medical diagnostic reagents and medical diagnostic assays for testing body fluids for medical determination of risk stratification of prostate cancer; diagnostic preparations for medical purposes; diagnostic agents for medical use

Human healthcare services; medical services; execution of medical tests for diagnostic or treatment purposes; medical diagnostic services, namely, medical testing for diagnostic or treatment purposes; health care services, namely, providing diagnostic tests for prostate cancer; online services relating to medical and diagnostic prostate cancer tests in the nature of medical and health care services related to prostate cancer testing through online services, providing online services in the nature of website featuring information, advice, and consultation related to prostate cancer diagnostic testing; prostate cancer screening services; execution of prostate cancer tests for diagnostic or treatment purposes; health care services, namely, providing prostate cancer diagnostics; medical testing services relating to prostate cancer; taking of blood samples; services for the testing of blood; performing diagnosis of diseases; medical testing for diagnostic or treatment purposes; medical services for the diagnosis of conditions of the human body; medical analysis for the diagnosis and treatment of persons; medical testing services relating to the diagnosis and treatment of disease; medical analysis services for the diagnosis of cancer; medical analysis services for cancer diagnosis and prognosis; providing information relating to medical results and diagnostic tests, namely, prostate cancer tests; providing information relating to medical test results; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical laboratory services for the analysis of samples and blood samples taken from patients; rental of equipment for human healthcare; advice, consultancy and information relating to the aforesaid, included in this class

Medical and veterinary apparatus and instruments, namely, apparatus to perform a diagnostic test for risk stratification of prostate cancer; diagnostic, examination and monitoring equipment for medical use, namely apparatus for medical diagnostic testing and risk stratification in the field of prostate cancer; testing apparatus for medical purposes, namely, human blood and specimen testing apparatus; medical test instruments for prostate cancer; testing probes for medical diagnostic purposes; testing instruments for medical diagnostic purposes; tools for medical diagnostics, namely, medical diagnostic apparatuses for testing for and forecasting risk of prostate cancer; apparatus for carrying-out diagnostic tests for medical purposes, namely, medical diagnostic apparatuses for testing of human body fluids

IT programming services in the nature of computer programming; software development, programming and implementation; web site hosting services; Software as a service (SAAS) services featuring software for diagnostic medical testing and related data analysis; rental of computer software; providing temporary use of on-line non-downloadable software for diagnostic medical testing and related data analysis; scientific and technology services, namely, diagnostic medical testing services for others for scientific research purposes; chemical and pharmaceutical research; medical and pharmacological research services; conducting clinical trials for others; scientific research for medical purposes in the area of cancerous diseases; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing information on clinical studies via an interactive website; medical and scientific laboratory services; advice, consultancy and information relating to the aforesaid, included in this class

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
May 26, 2024 NREP
CHANGE OF NAME/ADDRESS REC'D FROM IB
May 26, 2024 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Sep 9, 2023 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 14, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jan 23, 2023 FICS
FINAL DISPOSITION PROCESSED
Jan 23, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 27, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 27, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 27, 2022 R.PR
NOTIFICATION PROCESSED BY IB
Jul 18, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 12, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jul 12, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 29, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 29, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 22, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 7, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 6, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 6, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 6, 2022 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Jan 21, 2022 NREP
REFUSAL PROCESSED BY IB
Dec 26, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 8, 2021 RFCS
REFUSAL PROCESSED BY MPU
Dec 8, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 9, 2021 RFCR
NON-FINAL ACTION WRITTEN
Nov 8, 2021 CNRT
ASSIGNED TO EXAMINER
Sep 3, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 20, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 16, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 12, 2021 REPR